Fundz

REGENXBIO Appoints Mitchell Chan as Executive Vice President and Chief Financial Officer

PUBLIC · RGNXSep 17, 2024

Position

Chief Financial Officer

Company

REGENXBIO

Mitchell Chan
mchan@regenxbio.com
RockvilleBiotechnologyHealth Care

Description

REGENXBIO Inc announced the appointment of Mitchell Chan as Executive Vice President and Chief Financial Officer. Mr. Chan brings nearly two decades of biopharmaceutical financial leadership experience to REGENXBIO.

Quick answer

REGENXBIO Appoints Mitchell Chan as Executive Vice President and Chief Financial Officer (September 17, 2024). REGENXBIO is based in Rockville, Maryland, United States.

Who is the new Chief Financial Officer at REGENXBIO?
REGENXBIO named Mitchell Chan Chief Financial Officer, announced September 17, 2024.
What did REGENXBIO announce on September 17, 2024?
REGENXBIO Inc announced the appointment of Mitchell Chan as Executive Vice President and Chief Financial Officer. Mr. Chan brings nearly two decades of biopharmaceutical financial leadership experience to REGENXBIO.
What does REGENXBIO do?
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy.
Where is REGENXBIO based?
REGENXBIO is based in Rockville, Maryland, United States.
Which similar companies made leadership changes around the same time?
CivicaScript (September 17, 2024), 89bio (September 17, 2024), Nautilus Biotechnology (September 18, 2024) and Fairway Consulting Group (September 18, 2024) also announced leadership changes within 45 days of REGENXBIO.

Source: Fundz verified event record.

Other recent leadership changes in Biotechnology and Health Care

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Who to call at REGENXBIO, and when

A new leader at REGENXBIO brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day REGENXBIO raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at REGENXBIO, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at REGENXBIO. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

REGENXBIO

Location

9804 Medical Center Drive

Rockville, Maryland, United States

About

REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment REGENXBIO changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Ram
Senior decision-maker at this company
••••••••@••••••••

See Ram's verified email →

George
Senior decision-maker at this company
••••••••@••••••••

See George's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for REGENXBIO's next move

Learn about Strategic plan

REGENXBIO changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.